BioCentury | Oct 26, 2018
Clinical News

GSK, MorphoSys RA therapy misses in Phase IIb

...to receive methotrexate in combination with placebo or 22.5, 45, 90, 135 or 180 mg subcutaneous GSK3196165...
BioCentury | Oct 22, 2018
Clinical News

GSK, MorphoSys RA therapy misses in Phase IIb

...to receive methotrexate in combination with placebo or 22.5, 45, 90, 135 or 180 mg subcutaneous GSK3196165...
BioCentury | Apr 25, 2016
Clinical News

Subcutaneous GSK3196165: Phase II started

...GlaxoSmithKline began a double-blind, placebo-controlled, European Phase II trial to evaluate 8 injections of subcutaneous GSK3196165 over...
...2013). MorphoSys AG (Xetra:MOR), Martinsried, Germany GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Subcutaneous GSK3196165 (formerly Subcutaneous MOR103...
BioCentury | Dec 3, 2012
Clinical News

Subcutaneous MOR103: Phase I data

...trial in 32 healthy volunteers showed that single doses of 0.5, 1 and 2 mg/kg subcutaneous MOR103...
...by year end 2013 (see BioCentury, Sept. 24). MorphoSys AG (Xetra:MOR; Pink:MPSYF), Martinsried, Germany Product: Subcutaneous MOR103...
Items per page:
1 - 4 of 4